Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells

Albana Gattelli, Ivan Nalvarte, Anne Boulay, Tim C Roloff, Martin Schreiber, Neil Carragher, Kenneth K Macleod, Michaela Schlederer, Susanne Lienhard, Lukas Kenner, Maria I Torres-Arzayus, Nancy E Hynes

Research output: Contribution to journalArticlepeer-review

Abstract

We show that elevated levels of Ret receptor are found in different sub-types of human breast cancers and that high Ret correlates with decreased metastasis-free survival. The role of Ret in ER+ breast cancer models was explored combining in vitro and in vivo approaches. Our analyses revealed that ligand-induced Ret activation: (i) stimulates migration of breast cancer cells; (ii) rescues cells from anti-proliferative effects of endocrine treatment and (iii) stimulates expression of cytokines in the presence of endocrine agents. Indeed, we uncovered a positive feed-forward loop between the inflammatory cytokine IL6 and Ret that links them at the expression and the functional level. In vivo inhibition of Ret in a metastatic breast cancer model inhibits tumour outgrowth and metastatic potential. Ret inhibition blocks the feed-forward loop by down-regulating Ret levels, as well as decreasing activity of Fak, an integrator of IL6-Ret signalling. Our results suggest that Ret kinase should be considered as a novel therapeutic target in subsets of breast cancer.
Original languageEnglish
Pages (from-to)1335-1350
Number of pages16
JournalEMBO Molecular Medicine
Volume5
Issue number9
DOIs
Publication statusPublished - Sep 2013

Keywords

  • endocrine-therapy
  • Fak
  • IL6

Fingerprint

Dive into the research topics of 'Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells'. Together they form a unique fingerprint.

Cite this